Navigation Links
PDL BioPharma Announces Expiration and Preliminary Results of its Exchange Offer
Date:1/3/2012

INCLINE VILLAGE, Nev., Jan. 3, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced the expiration and preliminary results of its offer to exchange up to $180,000,000 in aggregate principal amount of outstanding 2.875% Convertible Senior Notes due 2015 (Old Notes), for a like principal amount of new 2.875% Series 2012 Convertible Senior Notes due 2015 (New Notes), and a cash payment.  The name of the New Notes has been amended from the previously-announced "2.875% Series 2011 Convertible Senior Notes due 2015" to reflect the expected issuance of the New Notes in 2012 instead of 2011.

(Logo:  http://photos.prnewswire.com/prnh/20110822/SF55808LOGO)

Based on the preliminary count by The Bank of New York Mellon Trust Company, N.A., the tender and paying agent for the exchange offer, a total of $168,972,000 aggregate principal amount of Old Notes, representing approximately 93.9% of the outstanding principal amount of the Old Notes, were properly tendered for exchange and not withdrawn.

In accordance with the terms and conditions of the exchange offer, and based on the preliminary count by the tender and paying agent, PDL expects to accept for exchange $168,972,000  principal amount of Old Notes for a like principal amount of New Notes and aggregate note exchange payments of $844,860. 

These amounts are preliminary and subject to confirmation by the tender and paying agent. The final results of the exchange offer will be announced promptly following completion of the confirmation process by the tender and paying agent. Settlement of the exchange offer is expected to occur on or around January 5, 2012.

The information agent for the exchange offer is Georgeson Inc. Holders of Old Notes who have questions may call the information agent at (866) 541-3547. Banks and brokers may call (212) 440-9800.

About PDL BioPharma

PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. Today, PDL is focused on intellectual property asset management, investing in new royalty bearing assets and maximizing the value of its patent portfolio and related assets. For more information, please visit www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.

 

Exchange Offer Statement
This press release is for informational purposes only and is neither an offer to buy nor the solicitation of an offer to sell the Old Notes.

Forward-looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.  Each of these forward-looking statements involves risks and uncertainties.  Actual results may differ materially from those, express or implied, in these forward-looking statements.     Important factors that could impair the value of the Company's royalty assets, restrict or impede the ability of the Company to invest in new royalty bearing assets and limit the Company's ability to pay dividends are disclosed in the risk factors contained in the Company's 2010 Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 1, 2011, and updated by subsequent Quarterly Reports on Form 10-Q. All forward-looking statements are expressly qualified in their entirety by such factors. We do not undertake any duty to update any forward-looking statement except as required by law.


'/>"/>
SOURCE PDL BioPharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Provenance Biopharmaceuticals Corp. Announces $8M Financing Arrangement
2. Inspiration Biopharmaceuticals Expands Leadership Team with Four New Hires
3. PDL BioPharma Provides Fourth Quarter 2011 Revenue Guidance of $72 Million
4. Perceptive Informatics Completes Over 500 System Integrations as the Biopharma Industry Continues to Adopt Seamless eClinical Solutions
5. Keryx Biopharmaceuticals Announces Phase 2 Data for KRX-0401 (Perifosine) in Hodgkins Lymphoma Presented at ASH Meeting
6. Inspiration Biopharmaceuticals Presents Key Scientific Data from its Two Lead Hemophilia Development Programs at the 53rd Annual Meeting of the American Society of Hematology (ASH)
7. NeoStem Appoints a Biopharmaceutical Business Leader and a Cellular Therapy Expert to its Board of Directors
8. Inspiration Biopharmaceuticals Initiates Second Pivotal Clinical Study of Innovative Hemophilia Therapy OBI-1
9. PAREXEL Strengthens Late Phase and Observational Research Capabilities With Expert Team to Help Biopharma Meet Commercialization Goals
10. Genesis Biopharmas Scientific and Medical Advisory Board Welcomes Dr. Steven A. Rosenberg, Chief of the Surgery Branch at the NCI
11. PDL BioPharma Inc. Announces Exchange Offer for Its 2.875% Convertible Senior Notes Due February 15, 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2017)... , Sept. 18, 2017 ... fields of bioinformatics and immune engineering, today ... protective avian influenza A (H7N9) vaccine. ... related to seasonal influenza and presents a ... on prior exposure to be effective. Using ...
(Date:9/12/2017)... SAN FRANCISCO , Sept. 12, 2017 /PRNewswire/ ... Lifecycle Management Solutions (VLMS), is pleased to announce ... as a member of its Board of Directors ... 2017. ValGenesis VLMS enables life science companies to ... eliminate the use of paper in this process. ...
(Date:9/7/2017)... 2017  Eli Lilly and Company (NYSE: ... operations to more efficiently focus resources on developing ... Global workforce reductions, including those from a U.S. ... approximately 3,500 positions. With the ... of approximately $500 million that will begin to ...
Breaking Medicine Technology:
(Date:9/26/2017)... ... ... Founded as an independent institute in 1968, The Glenholme School devoted ... 2018, Glenholme will celebrate its first 50 years and set a course for the ... ponies, was generously donated by Jean White Van Sinderen to Devereux in 1968. The ...
(Date:9/26/2017)... ... September 26, 2017 , ... The Organizing ... and tactical plans for Pittcon 2018. As of July 1, Adrian C. Michael, ... his named vice president, Charles Gardner, (ChemImage Corporation) and selected chairs. ...
(Date:9/26/2017)... ... September 26, 2017 , ... “Childhood Memories of a ... draw readers back, and help them relive their own youth. “Childhood Memories of a ... operator in the US Navy for nine years. He received his BS from ...
(Date:9/26/2017)... (PRWEB) , ... September 26, 2017 , ... Time out ... and a little boy's newfound understanding that even grownups make mistakes. “Time Out for ... Southwestern United States for her entire life and whose passion for children inspired her ...
(Date:9/25/2017)... ... September 25, 2017 , ... The Renal Support Network (RSN) is ... improved functionality and enhanced rich content focused on RSN’s mission to empower people who ... hopeful about their future. , Our unique website is loaded with hundreds of ...
Breaking Medicine News(10 mins):